Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9607559 | 1.00 | CA1 (0.50) | CA1CA9CYP1A2SMN1; SMN2 | |
| SCHEMBL9607558 | 1.00 | CA1 (0.50) | CA1CA9CYP1A2SMN1; SMN2 | |
| SCHEMBL13533896 | 0.86 | CA1 (0.46) | CA1CA9CYP1A2SMN1; SMN2 | |
| SCHEMBL13817904 | 0.86 | CA1 (0.46) | CA1CA9CYP1A2SMN1; SMN2 | |
| SCHEMBL9927430 | 0.82 | CA1 (0.46) | CA1CA9CYP1A2SMN1; SMN2 | |
| SCHEMBL22972533 | 0.79 | CA1 (0.43) | CA1CA9CYP1A2SMN1; SMN2 | |
| SCHEMBL9559189 | 0.76 | CA1 (0.44) | CA1CA9CYP1A2 | |
| SCHEMBL12182879 | 0.76 | CA1 (0.44) | CA1CA9CYP1A2 | |
| SCHEMBL25327380 | 0.76 | CA1 (0.41) | CA1CA9CYP1A2 | |
| SCHEMBL9436287 | 0.74 | CA1 (0.39) | CA1CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230339930-A1 | Antiviral Heteroaryl Ketone Derivatives | PFIZER INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-03-09 | — | — | US | disclosed |
| US-11505535-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11339139-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200407336-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. (US) | 2020-12-31 | — | — | US | disclosed |
| US-10752605-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10450290-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190292163-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | CORSAIR PHARMA INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-20090325961-A1 | INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-31 | — | — | US | disclosed |
| US-7592461-B2 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-7553842-B2 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | ARRAY BIOPHARMA INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-29 | — | — | US | disclosed |
| US-7326728-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326728-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20070185056-A1 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070179189-A1 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505535-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | CA1 3025/4885CA9 1651/4885CYP1A2 54/4885 |
| US-10752605-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | CA1 3025/4885CA9 1651/4885CYP1A2 54/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | CA1 2179/4885CA9 549/4885CYP1A2 4331/4885 |
| US-20230339930-A1 | Antiviral Heteroaryl Ketone Derivatives | ACE2, ZC3HAV1, SARS1 | CA1 4850/4885CA9 4313/4885CYP1A2 77/4885 |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, VKORC1, PANK3 | CA1 3831/4885CA9 1781/4885CYP1A2 503/4885 |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | CA1 4323/4885CA9 3315/4885CYP1A2 1055/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | CA1 3831/4885CA9 1781/4885CYP1A2 503/4885 |
| US-20090325961-A1 | INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB1, NR3C1, NR5A1 | CA1 4048/4885CA9 2804/4885CYP1A2 1638/4885 |
| US-20090030046-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, HK1 | CA1 3621/4885CA9 2029/4885CYP1A2 3973/4885 |
| US-20200407336-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | CA1 3025/4885CA9 1651/4885CYP1A2 54/4885 |
| US-20070185056-A1 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof | NFKB1, NR3C1, NR5A1 | CA1 4063/4885CA9 2896/4885CYP1A2 1575/4885 |
| US-11339139-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | CA1 3025/4885CA9 1651/4885CYP1A2 54/4885 |
| US-20190292163-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | CA1 3025/4885CA9 1651/4885CYP1A2 54/4885 |
| US-20070179189-A1 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKBIA, NFKB2 | CA1 4167/4885CA9 1410/4885CYP1A2 1675/4885 |
| US-10450290-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | CA1 3025/4885CA9 1651/4885CYP1A2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.